

Alexandra Borodovsky

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10993009/publications.pdf>

Version: 2024-02-01

15
papers

1,040
citations

933447

10
h-index

1125743

13
g-index

15
all docs

15
docs citations

15
times ranked

2004
citing authors

#	ARTICLE	IF	CITATIONS
1	A pharmacokinetic-pharmacodynamic model for the MET tyrosine kinase inhibitor, savolitinib, to explore target inhibition requirements for anti-tumour activity. British Journal of Pharmacology, 2021, 178, 600-613.	5.4	5
2	Evaluation of Combination Strategies for the A2AR Inhibitor AZD4635 Across Tumor Microenvironment Conditions via a Systems Pharmacology Model. Frontiers in Immunology, 2021, 12, 617316.	4.8	10
3	Small molecule AZD4635 inhibitor of A _{2A} signaling rescues immune cell function including CD103 ⁺ dendritic cells enhancing anti-tumor immunity. , 2020, 8, e000417.		65
4	Adenosine Signaling Is Prognostic for Cancer Outcome and Has Predictive Utility for Immunotherapeutic Response. Clinical Cancer Research, 2020, 26, 2176-2187.	7.0	54
5	Demethylation and epigenetic modification with 5-azacytidine reduces IDH1 mutant glioma growth in combination with temozolomide. Neuro-Oncology, 2019, 21, 189-200.	1.2	49
6	Development of a quantification method for adenosine in tumors by LC-MS/MS with dansyl chloride derivatization. Analytical Biochemistry, 2019, 568, 78-88.	2.4	22
7	Abstract 3751: Inhibition of A2AR by AZD4635 induces anti-tumor immunity alone and in combination with anti-PD-L1 in preclinical models. Cancer Research, 2018, 78, 3751-3751.	0.9	8
8	Synergistic and targeted therapy with a procaspase-3 activator and temozolomide extends survival in glioma rodent models and is feasible for the treatment of canine malignant glioma patients. Oncotarget, 2017, 8, 80124-80138.	1.8	33
9	Repurposing the Antihelminthic Mebendazole as a Hedgehog Inhibitor. Molecular Cancer Therapeutics, 2015, 14, 3-13.	4.1	78
10	A model of a patient-derived IDH1 mutant anaplastic astrocytoma with alternative lengthening of telomeres. Journal of Neuro-Oncology, 2015, 121, 479-487.	2.9	14
11	ET-08 * DEMETHYLATING THERAPY INDUCES DIFFERENTIATION AND THERAPEUTIC RESPONSE IN IDH1 MUTANT MALIGNANT GLIOMAS. Neuro-Oncology, 2014, 16, v80-v80.	1.2	0
12	Itraconazole and Arsenic Trioxide Inhibit Hedgehog Pathway Activation and Tumor Growth Associated with Acquired Resistance to Smoothed Antagonists. Cancer Cell, 2013, 23, 23-34.	16.8	296
13	5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft. Oncotarget, 2013, 4, 1737-1747.	1.8	141
14	Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine. Oncotarget, 2013, 4, 1729-1736.	1.8	213
15	Altered cancer cell metabolism in gliomas with mutant IDH1 or IDH2. Current Opinion in Oncology, 2012, 24, 83-89.	2.4	52